Introduction: Generic pharmaceuticals account for the majority of the 359billionUSpharmaceuticalmarket,includingforcardiologydrugs.Amidstalackofpricetransparencyandadministrativeinefficiencies,genericdrugpricesarehigh,causinganundueburdenonpatients.Methods:Weidentifiedthe50mostusedgenericcardiologydrugsbyvolumeperthe2020MedicarePartDspendingdata.WeextractedcostperdoseofeachdrugfromtheMarcCubanCostPlusDrugCompany(MCCPDC)websiteandestimatedtheaggregatecostsavingsifMCCPDCwereemployedonanationalscalebycalculatingthedifferencebetweenthiscostandMedicarespending.Results:Medicarespent7.7 billion on the 50 most used generic cardiology drugs by volume in 2020 according to Medicare Part D data. Pharmacy and shipping costs accounted for a substantial portion of expenditures. Per our most conservative estimate, 1.3billion(172.9 billion (38%) savings for 35 of 50 drugs. Discussion: There is enormous potential for cost savings in the US market for generic cardiology drugs. By encouraging increased competition, decreasing administrative costs, and advocating for our patients to compare prices between the MCCPDC and other generic pharmaceutical dispensers, we have the potential to improve access to care and corresponding outcomes for cardiology patients